New treatment options with repeated intravitreal injections of inhibitors of vascular endothelial growth factor (VEGF) for nAMD have had a significant positive impact on the prevalence of blindness due to this condition.[9] The burden of this age-related disorder is now more related to visual morbidity due to poor quality of vision rather than blindness.[10]. The gene discussed is VEGFA; the disease is blindness (disorder).